The ideas behind personalized medicine and systems biology require information from a variety of analyses be combined to generate a more complete picture of the entire biological system. This might be thought of simplistically as having two solutions. One is integrative analysis where data from a collection of disparate experiments is combined using informatics and modelling to generate the system-wide picture. The other is a unified approach where traditionally separate analyses are combined into a single analytical event, which yeilds information on the entire system under study. The application of existing technologies already allows us to investigate the unified approach for studying enzyme systems. By developing methods that can quantify protein and small molecules, the enzyme of interest, co-enzymes, substrate, co-factors and metabolites can all be quantified in a single experiment. Extension of the idea to multiple enzyme pathways might produce a more complete picture of the larger system with less variability and noise than an integrative approach.
What will you learn?
- The collection of tools that make unified molecular analysis possible
- The current challenges associated with unified analysis
- Future opportunities for improvements in technology and methodology to support unified analysis of biological systems.
Who should attend?
- Users of AB SCIEX LC and MS products looking to implement novel workflows
- Managers searching for new capabilities that add value
- Researchers in systems biology
- Scientists involved with discovering and validating molecular biomarkers.
Richard King graduated from SUNY College of Environmental Science and Forestry at Syracuse with a BS in Chemistry in 1986. He obtained his PhD in Analytical Chemistry from Drexel University in 1994 under the direction of Kevin Owens. The subject of his thesis was ‘MALDI TOF MS Instrumentation and Mechanisms’. He joined the Department of Drug Metabolism at Merck Research Laboratories, West Point, Pennsylvania in 1994 where he worked in Preclinical Drug Metabolism with responsibilities related to bioanalysis and new technology development and implementation until 2008. In the fall of 2008 King became one of the founding members of PharmaCadence Analytical Services, LLC of Hatfield, PA, USA.